BioCentury | Apr 15, 2013
Clinical News

OncorMed, Cancer Research Campaign Technology, Duke University regulatory update

...Cancer Research and Duke any revenues generated from therapeutic licenses. Oncormed Inc. (ONM), Gaithersburg, Md. Cancer Research Campaign Technology...
BioCentury | Dec 19, 2005
Strategy

Cyclacel funding history

...Dresdner Kleinwort; Equitable Life Assurance; Merifin Capital; Northern Venture Managers; Scottish Equity Partnership; Merlin Biosciences; Cancer Research Campaign Technology...
BioCentury | Aug 4, 2003
Strategy

Bellwether thinking

...the old-fashioned way. Founded in 1996 by Merlin Ventures, which provided the seed finance, and Cancer Research Campaign Technology...
BioCentury | Aug 30, 2001
Company News

ASM in-licenses cancer compound

Antisoma (LSE:ASM; NASD-EU:ASOM) in-licensed a vascular targeting agent, DMXAA (5,6-dimethylxanthenone-4-acetic acid), from Cancer Research Ventures (London, U.K.), the Cancer Research Campaign's technology transfer arm. ASM said that in Phase I trials, the compound used as...
BioCentury | Jan 29, 2001
Company News

Cancer Research Campaign Technology Ltd., Cancer Research Ventures Ltd. deal

...Ventures will exclusively conduct technology transfer activities for business opportunities derived from research funded by Cancer Research Campaign Technology...
...spun out of the CRCT in 1998 to handle technology transfer outside Cancer Research Campaign. Cancer Research Campaign Technology...
BioCentury | Dec 7, 2000
Financial News

Vernalis banks 2.75 million

...divested its holding in Cancer Research Ventures (London, U.K.), the licensing and technology subsidiary of Cancer Research Campaign Technology...
BioCentury | Sep 11, 2000
Company News

Viragen, University of Nottingham deal

...as a cancer vaccine . The technology was developed at the university and the U.K.’s Cancer Research Campaign Technology...
BioCentury | Aug 28, 2000
Company News

Viragen, Cancer Research Campaign Technology Ltd., University of Nottingham deal

...complement inhibitor CD55 to treat breast, ovarian and colorectal cancers. Viragen Inc. (VRA), Plantation, Fla. Cancer Research Campaign Technology...
BioCentury | Jul 31, 2000
Company News

Viragen, Cancer Research Campaign Technology Ltd., University of Nottingham deal

...discovered at a Cancer Research Campaign laboratory at the university. Viragen Inc. (VRA), Plantation, Fla. Cancer Research Campaign Technology...
BioCentury | May 1, 2000
Strategy

Vanguard, CeNeS seek mass

...Northridge, Calif.). In addition, VGD intends to develop anti-cancer compounds through an agreement with the Cancer Research Campaign Technology...
Items per page:
1 - 10 of 25
BioCentury | Apr 15, 2013
Clinical News

OncorMed, Cancer Research Campaign Technology, Duke University regulatory update

...Cancer Research and Duke any revenues generated from therapeutic licenses. Oncormed Inc. (ONM), Gaithersburg, Md. Cancer Research Campaign Technology...
BioCentury | Dec 19, 2005
Strategy

Cyclacel funding history

...Dresdner Kleinwort; Equitable Life Assurance; Merifin Capital; Northern Venture Managers; Scottish Equity Partnership; Merlin Biosciences; Cancer Research Campaign Technology...
BioCentury | Aug 4, 2003
Strategy

Bellwether thinking

...the old-fashioned way. Founded in 1996 by Merlin Ventures, which provided the seed finance, and Cancer Research Campaign Technology...
BioCentury | Aug 30, 2001
Company News

ASM in-licenses cancer compound

Antisoma (LSE:ASM; NASD-EU:ASOM) in-licensed a vascular targeting agent, DMXAA (5,6-dimethylxanthenone-4-acetic acid), from Cancer Research Ventures (London, U.K.), the Cancer Research Campaign's technology transfer arm. ASM said that in Phase I trials, the compound used as...
BioCentury | Jan 29, 2001
Company News

Cancer Research Campaign Technology Ltd., Cancer Research Ventures Ltd. deal

...Ventures will exclusively conduct technology transfer activities for business opportunities derived from research funded by Cancer Research Campaign Technology...
...spun out of the CRCT in 1998 to handle technology transfer outside Cancer Research Campaign. Cancer Research Campaign Technology...
BioCentury | Dec 7, 2000
Financial News

Vernalis banks 2.75 million

...divested its holding in Cancer Research Ventures (London, U.K.), the licensing and technology subsidiary of Cancer Research Campaign Technology...
BioCentury | Sep 11, 2000
Company News

Viragen, University of Nottingham deal

...as a cancer vaccine . The technology was developed at the university and the U.K.’s Cancer Research Campaign Technology...
BioCentury | Aug 28, 2000
Company News

Viragen, Cancer Research Campaign Technology Ltd., University of Nottingham deal

...complement inhibitor CD55 to treat breast, ovarian and colorectal cancers. Viragen Inc. (VRA), Plantation, Fla. Cancer Research Campaign Technology...
BioCentury | Jul 31, 2000
Company News

Viragen, Cancer Research Campaign Technology Ltd., University of Nottingham deal

...discovered at a Cancer Research Campaign laboratory at the university. Viragen Inc. (VRA), Plantation, Fla. Cancer Research Campaign Technology...
BioCentury | May 1, 2000
Strategy

Vanguard, CeNeS seek mass

...Northridge, Calif.). In addition, VGD intends to develop anti-cancer compounds through an agreement with the Cancer Research Campaign Technology...
Items per page:
1 - 10 of 25